First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282 | Completed Phase 1 FDA Drug

• 3 other identifiers: TED16132U1111-1223-44102019-001018-40
• Study Type: interventional
• Target: 37
• Locations: 6 countries
• Sites: 12

Brief Summary

Primary Objectives:

• Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
• Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM Secondary Objectives:
• To characterize the safety profile of SAR442085
• To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent
• To evaluate the potential immunogenicity of SAR442085
• To assess preliminary evidence of antitumor activity in the Dose Escalation Part A

Conditions

Plasma Cell Myeloma

Outcome Measures

Primary Outcomes (3)

• The maximum tolerated dose (MTD) of SAR442085 (Part A)

  MTD is defined as the dose level with highest probability of investigational medicinal product (IMP) related dose limiting toxicity (DLT) rate within the target range (16 to 33%) among dose levels with less than 0.25 probability of DLT rate above target (\>33%)

  At the end of Cycle 1 (each cycle is approximately 28 days)

• Recommended Phase 2 dose (RP2D) (Part A)

  RP2D is defined as the dose selected for the further single agent testing - including in Phase 1 expansion part B.

  At the end of Cycle 1 (each cycle is approximately 28 days)

• Overall response rate (Part B)

  Overall response rate (ORR): is defined as the proportion of patients with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR), using the International Myeloma Working Group (IMWG) criteria.

  approximately 6 months after the last patient has started treatment in Part B (approx. 2 years)

Secondary Outcomes (7)

• Treatment-emergent adverse events (AEs)/serious adverse events (SAE) (Both Part A and B)

  From baseline to end of treatment + 30 days (approx. 2 years)

• PK parameters of SAR442085: Cmax (Both Part A and B)

  Cycle 1 Day 1 to Day 28

• PK parameters of SAR442085: Tmax (Both Part A and B)

  Cycle 1 Day 1 to Day 28

• PK parameters of SAR442085: AUC (Both Part A and B)

  Cycle 1 Day 1 to Day 28

• Anti-drug antibody (ADA) against SAR442085 (Both Part A and B)

  Cycle 1, 2, 3, 6 and 9 (each cycle is approximately 28 days)

Study Arms (2)

Part A: SAR442085 dose escalation

EXPERIMENTAL

SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.

Drug: SAR442085

Part B: SAR442085 dose expansion

EXPERIMENTAL

SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.

Drug: SAR442085

Interventions

SAR442085 DRUG

Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Part A: SAR442085 dose escalation; Part B: SAR442085 dose expansion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be at least 18 years of age or of the country's legal age of majority if the legal age is \>18 years old, at the time of signing the informed consent.
• Participant has given voluntary written informed consent.
• Participant has been previousy diagnosed with multiple myeloma based on standard criteria.
• Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior lines of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide), at least 1 anti-CD38 monoclonal antibody and at least 1 steroid. Applicable countries in EU and Asia can enroll anti-CD38 naive RRMM patients from DL4 and onwards. (3) Participant had at least a minimal response (MR) to the anti-CD38 antibody containing regimen and had last dose of anti-CD38 monoclonal antibody at least 9 months prior to study entry. Applicable countries in EU and Asia can enroll anti-CD38 naive RRMM patients from DL4 and onwards.
• Part B and the last cohort(s) of Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior line of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide) and at least 1 steroid. (3) Prior therapy has not included an anti-CD38 monoclonal antibody.
• Participant has myeloma disease progression on or after last therapy.
• Participant must have measurable disease as defined as at least one of the following:
• Serum M protein ≥0.5 g/dL (≥5 g/L)
• Urine M protein ≥200 mg/24 hours
• Serum FLC assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum
• FLC ratio (\<0.26 or \>1.65).
• A male participant must agree to use contraception during the intervention period and for at least 150 days after the last dose of study drug and refrain from donating sperm during this period.
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
• Not a woman of childbearing potential (WOCBP)
• A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 150 days after the last dose of study intervention.

You may not qualify if:

• Participant is diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, superficial bladder carcinoma or low risk prostate cancer.
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score \>2.
• Participant has a history of Chronic obstructive pulmonary disease (COPD) or asthma.
• Participant has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade ≤1 or baseline (exception: alopecia).
• Participant has congestive heart failure (New York Heart Association) Grade ≥II; cardiac myopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension, QT interval corrected by the Fridericia method \>480 msec (Grade ≥2).
• Participant has had acute myocardial infarction within 6 months before first dose of study medication.
• Participant has ongoing sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade ≥3.
• Participant has active autoimmune disease including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily.
• Known acquired immunodeficiency syndrome (AIDS) or related illnesses or human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or to have active hepatitis A, B (defined as a known positive hepatitis B surface antigen (HBsAg) result or positive HepB DNA), or C (defined as a known quantitative hepatitis C \[HCV\] ribonucleic acid RNA results greater than the lower limits of detection of the assay or positive HCV antigen) infection.
• Participant has positive Coombs test at baseline.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sponsors & Collaborators

• Sanofi: lead

Study Sites (12)

City of Hope Site Number : 8400002

Duarte, California, 91010, United States

Location

Dana Farber Cancer Institute Site Number : 8400003

Boston, Massachusetts, 02115, United States

Location

Mayo Clinic of Rochester Site Number : 8400005

Rochester, Minnesota, 55905, United States

Location

UNC Chapel Hill Site Number : 8400006

Chapel Hill, North Carolina, 27599, United States

Location

Froedtert Hospital & Medical College of Wisconsin Site Number : 8400004

Milwaukee, Wisconsin, 53226, United States

Location

Investigational Site Number : 2030002

Brno, 62500, Czechia

Location

Investigational Site Number : 2030003

Ostrava - Poruba, 70852, Czechia

Location

Investigational Site Number : 2030001

Prague, 12808, Czechia

Location

Investigational Site Number : 2500001

Toulouse, 31059, France

Location

Investigational Site Number : 3000001

Athens, 11528, Greece

Location

Investigational Site Number : 7240001

Salamanca, Salamanca, 37007, Spain

Location

Investigational Site Number : 1580001

Taipei, 10002, Taiwan

Location

Related Publications (1)

• Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Mace S, van de Velde H, Richardson PG. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2024 Nov;113(5):593-605. doi: 10.1111/ejh.14270. Epub 2024 Jul 12.

  PMID: 38993150 BACKGROUND

Related Links

• TED16132 Plain Language Results Summary

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Clinical Sciences & Operations

  Sanofi

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2019
• First Posted: June 27, 2019
• Study Start: August 19, 2019
• Primary Completion: August 29, 2022
• Study Completion: September 4, 2023
• Last Updated: September 12, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

FR (1); GR (1); CZ (3); US (5); ES (1); TW (1)